Background: Maintenance hemodialysis (MHD) can lead to hypertrophy of myocardial cells and interstitial fibrosis in patients, which can ultimately culminate in left ventricular hypertrophy (LVH). The objective of this study is to examine the expression of miR-107 in patients undergoing MHD who also present with LVH and to evaluate its predictive value.

Methods: A total of 135 patients with end-stage renal disease who were undergoing MHD were included as the research subjects. Patients were grouped based on left ventricular mass index. Real-time quantitative polymerase chain reaction was used to detect the expression of miR-107 in the serum of the patients. The receiver operating characteristic curve was used to evaluate the diagnostic value of miR-107 in MHD with LVH patients. The Pearson’s method was used for correlation analysis. Logistic regression model was used to analyze the risk factors for cardiac hypertrophy in MHD patients.

Results: Serum miR-107 is highly expressed in patients with MHD and LVH, and it may be a potential diagnostic biomarker. miR-107 has relatively high sensitivity and specificity in predicting LVH in patients with MHD. Serum miR-107 is closely related to the serum high-sensitivity C-reactive protein level and echocardiographic characteristics of patients with MHD combined with LVH. MiR-107 correlates with echocardiographic characteristics of MHD patients with LVH. Finally, logistic regression analysis indicated that miR-107 was a risk factor for LVH in MHD patients.

Conclusion: Serum miR-107 may have significant potential in diagnosing cardiac hypertrophy in MHD patients and is a potential biological indicator for cardiac hypertrophy in MHD patients.